TARGET AUDIENCE
This educational activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

OVERVIEW OF ACTIVITY
Clinical controversies and uncertainties persist in the management of all common cancers, and thousands of ongoing research trials worldwide attempt to provide new answers to long-standing clinical questions. As these trials reach maturity, clinical investigators initially present new data in abridged format at large scientific conferences and subsequently in full data sets formally published as part of peer-reviewed journals. Today, numerous annual oncology conferences release new clinical data and hundreds of peer-reviewed publications feature articles related to cancer research, treatment and practical management. The extensive list of available treatment options poses a challenge to the practicing clinician who must maintain knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors.

These proceedings from a daylong symposium combine the perspectives of 16 renowned investigators with a review of key recent presentations and publications across lung cancer, gastrointestinal cancers, melanoma, genitourinary cancers, multiple myeloma, breast cancer and Hodgkin and non-Hodgkin lymphoma to assist medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals in the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers.
Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation.
Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.
Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Kenneth C Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

Tanios Bekaii-Saab, MD
Co-Leader
GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Scottsdale, Arizona

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Merck, Taiho Oncology Inc; Data and Safety Monitoring Board: Exelixis Inc, Silagen.

Ian W Flinn, MD, PhD
Director of Blood Cancer Research
Sarah Cannon Research Institute
Tennessee Oncology
Nashville, Tennessee

Contracted Research: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Takeda Oncology.

William J Gradishar, MD
Betsy Bramsen Professor of Breast Oncology
Professor of Medicine
Director, Maggie Daley Center for Women’s Cancer Care
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

No relevant conflicts of interest to disclose.

Melissa Johnson, MD
Associate Director
Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Consulting Agreements: Astellas Pharma Global Development Inc, Otsuka Pharmaceutical Co Ltd.

Jason J Luke, MD
Assistant Professor of Medicine
University of Chicago
Chicago, Illinois

Consulting Agreements: Amgen Inc, Array BioPharma Inc; Contracted Research: AbbVie Inc, BBI Therapeutics, Bristol-Myers Squibb Company, Celldex Therapeutics, Corvus Pharmaceuticals, Delcath Systems Inc, EMD Serono Inc, Five Prime Therapeutics Inc, Genentech BioOncology, Incyte Corporation, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company.

Loretta J Nastoupil, MD
Assistant Professor
Department of Lymphoma/Myeloma
Division of Cancer Medicine
Director, Lymphoma Outcomes Database
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, TG Therapeutics Inc; Consulting Agreement: Gilead Sciences Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, TG Therapeutics Inc.

Robert Z Orlowski, MD, PhD
Director, Myeloma Section
Florence Maude Thomas Cancer Research Professor
Departments of Lymphoma/Myeloma and Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, FORMA Therapeutics, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Spectrum Pharmaceuticals Inc, Takeda Oncology.

Geoffrey R Oxnard, MD
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: ARIAD Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Inivata, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc.

Philip A Philip, MD, PhD
Professor of Oncology and Medicine
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Advisory Committee: bioTheranostics Inc, Caris Life Sciences, Celgene Corporation, EMD Serono Inc, Halozyme Therapeutics, Lexicon Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc; Contracted Research: Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Incyte Corporation, Karyopharm Therapeutics, Lilly, Merck, Momenta Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Taiho Oncology Inc, XBiotech; Speakers Bureau: Amgen Inc, Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation.

Elizabeth R Plimack, MD, MS
Director, Genitourinary Clinical Research
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Advisory Committee: Acceleron Pharma, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Consulting Agreements: Bristol-Myers Squibb Company, Lilly, Pfizer Inc; Contracted Research: Acceleron Pharma, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Lilly, Merck, Pfizer Inc.

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee and Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Exelixis Inc, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi.

Naiyer Rizvi, MD
Professor of Medicine
Director of Thoracic Oncology and Phase I Immunotherapeutics
Price Chair in Clinical Translational Research
Columbia University Medical Center
New York, New York

Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Ownership Interest: Gritstone Oncology.

George W Sledge Jr, MD
Professor of Medicine
Chief, Division of Oncology
Department of Medicine
Stanford University School of Medicine
Stanford, California

Board of Directors: Syndax Pharmaceuticals Inc; Contracted Research: Lilly; Scientific Advisory Board: Nektar, Radius Health Inc, Symphogen A/S.

Jeffrey Weber, MD, PhD
Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, New York

Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation; Stock Ownership: Altor Bioscience Corp, Celldex Therapeutics, CytomX Therapeutics; Scientific Advisory Board: Altor Bioscience Corp, Celldex Therapeutics, CytomX Therapeutics, Lion Biotechnologies.

Michael E Williams, MD, ScM
Byrd S Leavell Professor of Medicine
Chief, Hematology/Oncology Division
University of Virginia School of Medicine
Charlottesville, Virginia

Advisory Committee and Consulting Agreements: Celgene Corporation, Gilead Sciences Inc, Takeda Oncology, TG Therapeutics Inc; Contracted Research: Allos Therapeutics, Celgene Corporation, Gilead Sciences Inc, Takeda Oncology.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Therapeutics, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, bioTheranostics Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Janssen Biotech Inc, Lilly, Medivation Inc, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Sanofi, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: March 2017
Expiration date: March 2018